Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S.
Company facts
| Company | ACADIA Pharmaceuticals Inc. |
|---|---|
| Symbol | ACAD |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $4.78B (Massive market data, 2026-09-10) |
| Employees | 798 |
| Country | United States |
| Website | https://www.acadia.com |
Trading — ACADIA Pharmaceuticals Inc.
| Last price | $27.83 |
|---|---|
| Change | 0.32% |
| Previous close | $27.74 |
| Day range | $27.74 – $28.24 |
| 50-day average | $27.48 |
| 200-day average | $24.55 |
| Average volume | 1,715,733 |
Price basis: yfinance_daily_bar_close · 2026-09-11T21:07:44.986755+00:00
Valuation and financial health
| Earnings per share | $2.21 |
|---|---|
| Price / book | 3.66 |
| Price / cash flow | 29.81 |
| Enterprise value / EBITDA | 47.28 |
| Enterprise value / sales | 3.86 |
| Debt / equity | 0.00 |
| Current ratio | 3.39 |
| Dividend yield | 0.00% |
| Free cash flow | $145.62M |
| Cash ratio | 1.07 |
| Enterprise value | $4.39B |
Reported 2026-09-10
Earnings
| Report date | 2026-11-04 |
|---|---|
| Session | After Hours |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $0.21 |
| Year-ago EPS | $0.26 |
| Analyst estimates | 8 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ACAD are on the IntelTrends dashboard.